Eli Lilly: oral Foundayo cut sleep apnea index 43.8% in Phase 3 ATTAIN-OSA trial

Eli Lilly and Co. presented new Phase 3 data on its oral GLP-1 agent Foundayo (orforglipron) on Monday, 9 November 2026, according to ad-hoc-news.de. The ATTAIN-OSA results concern adults with overweight or obesity and show a reduction in sleep apnea severity. Lilly issued the announcement on the day of the presentation at the American Heart Association Scientific Sessions. ad-hoc-news.dead-hoc-news.dead-hoc-news.deOpen source ↗

Full study details are given in the company's release. The program enrolled 712 participants in two independent studies. After 52 weeks, the apnea-hypopnea index fell by 43.8 percent in participants not using PAP therapy and by 27.5 percent in those using it.

Sleep apnea and weight results

Without PAP therapy, 31.5 percent of Foundayo participants reached remission or only mild sleep apnea; in the PAP group the share was 19.6 percent. Sleep apnea-specific hypoxic burden decreased by 55.9 and 45.8 percent, respectively.

Participants lost on average 11.5 percent of body weight without PAP therapy and 11.2 percent with PAP therapy. Lilly also reported lower inflammation markers and a decline in systolic blood pressure. ad-hoc-news.dead-hoc-news.dead-hoc-news.deOpen source ↗

Safety and next regulatory step

The most common adverse events were gastrointestinal. Discontinuations due to adverse events occurred in 12.2 percent of participants without PAP therapy and in 6.8 percent of those with PAP therapy; with placebo the rates were 3.8 and 0.6 percent, respectively.

Lilly plans to submit Foundayo to the US Food and Drug Administration by the end of 2026 for the treatment of moderate to severe obstructive sleep apnea in adults with overweight or obesity. The outcome of the review remains open. The results point to a possible extension of use beyond weight reduction, but they do not replace an additional approval, and the sleep apnea indication has not yet been granted.